An agent used (usually in combination with levodopa) to treat idiopathic parkinson’s disease. Carbidopa blocks the peripheral conversion of levodopa to dopamine, allowing greater amounts of levodopa to penetrate the brain. Because carbidopa does not itself cross the blood-brain barrier to any significant extent, it does not inhibit the conversion of levodopa to dopamine within the brain. Marketed under the brand name lodosyn.
An inhibitor used to enable levodopa to enter the brain in larger quantities in the treatment of Parkinson’s disease.
A drug used with levodopa to treat parkinsonism.